Tourmaline Bio Inc (TRML)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2019 | 12-2017 | 12-2006 | |
| Cash Flows From Operating Activities | |||
| Net Income | -18,155 | N/A | N/A |
| Depreciation Amortization | 379 | N/A | N/A |
| Accounts payable and accrued liabilities | 321 | N/A | N/A |
| Other Working Capital | -85 | N/A | N/A |
| Other Operating Activity | -120 | 0 | 0 |
| Operating Cash Flow | $-17,660 | $N/A | $N/A |
| Cash Flows From Investing Activities | |||
| PPE Investments | -562 | N/A | N/A |
| Investing Cash Flow | $-562 | $N/A | $N/A |
| Cash Flows From Financing Activities | |||
| Common Stock Issued | 4 | N/A | N/A |
| Other Financing Activity | 36,200 | 0 | 0 |
| Financing Cash Flow | $36,204 | $N/A | $N/A |
| Beginning Cash Position | 20,997 | N/A | N/A |
| End Cash Position | 38,978 | N/A | N/A |
| Net Cash Flow | $17,982 | $N/A | $N/A |
| Free Cash Flow | |||
| Operating Cash Flow | -17,660 | N/A | N/A |
| Capital Expenditure | -562 | N/A | N/A |
| Free Cash Flow | -18,222 | 0 | 0 |